Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 04/28/25
What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 EarningsZacks Investment Research • 04/24/25
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/22/25
Regeneron signs over $3 billion deal with contract drugmaker to boost US manufacturingReuters • 04/22/25
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic MedicinesGlobeNewsWire • 04/22/25
FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 BillionBusiness Wire • 04/22/25
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License ApplicationGlobeNewsWire • 04/18/25
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)GlobeNewsWire • 04/18/25
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaGlobeNewsWire • 04/18/25
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkbackCNBC • 04/10/25
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play OutSeeking Alpha • 04/09/25